Shares of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) have earned a consensus rating of “Buy” from the ten analysts that are presently covering the firm, MarketBeat.com reports. Ten investment analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $8.95.
INFI has been the topic of several research reports. Wells Fargo & Company raised Infinity Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $4.00 to $14.00 in a research report on Wednesday, July 28th. HC Wainwright assumed coverage on shares of Infinity Pharmaceuticals in a report on Monday, October 18th. They issued a “buy” rating and a $9.00 price objective on the stock. JPMorgan Chase & Co. raised shares of Infinity Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $6.00 price objective on the stock in a report on Monday, August 2nd. B. Riley dropped their price objective on shares of Infinity Pharmaceuticals from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Wednesday, July 28th. They noted that the move was a valuation call. Finally, Zacks Investment Research raised shares of Infinity Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.50 price objective on the stock in a report on Wednesday, October 6th.
A number of large investors have recently modified their holdings of the business. Citigroup Inc. lifted its holdings in Infinity Pharmaceuticals by 141.7% during the third quarter. Citigroup Inc. now owns 10,073 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 5,906 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Infinity Pharmaceuticals by 41.6% in the second quarter. Bank of America Corp DE now owns 24,958 shares of the biotechnology company’s stock worth $75,000 after buying an additional 7,336 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Infinity Pharmaceuticals by 31.9% in the third quarter. Invesco Ltd. now owns 30,832 shares of the biotechnology company’s stock worth $105,000 after buying an additional 7,448 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Infinity Pharmaceuticals by 19.8% in the second quarter. Price T Rowe Associates Inc. MD now owns 46,944 shares of the biotechnology company’s stock worth $140,000 after buying an additional 7,744 shares in the last quarter. Finally, IFP Advisors Inc purchased a new position in shares of Infinity Pharmaceuticals in the third quarter worth $27,000. 55.14% of the stock is currently owned by institutional investors and hedge funds.
Infinity Pharmaceuticals (NASDAQ:INFI) last announced its quarterly earnings results on Tuesday, November 2nd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. The firm had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.45 million. Infinity Pharmaceuticals had a negative return on equity of 172.12% and a negative net margin of 2,398.81%. During the same period in the prior year, the company posted ($0.16) earnings per share. Equities research analysts anticipate that Infinity Pharmaceuticals will post -0.53 EPS for the current fiscal year.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.
Featured Article: Understanding debt-to-equity ratio in fundamental analysis
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.